49P Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation

Autor:	A. Baramidze, C. Gessner, M. Gogishvili, A. Sezer, T. Makharadze, S. Kilickap, M. Gumus, X. He, G. Gullo, P. Rietschel, R. Quek
Rok vydání:	2023
Předmět:	Pulmonary and Respiratory Medicine Oncology
Zdroj:	Journal of Thoracic Oncology. 18:S70-S71
ISSN:	1556-0864
DOI:	10.1016/s1556-0864(23)00303-9
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8cab2c6db0da7f8a417e66c76d464677 https://doi.org/10.1016/s1556-0864(23)00303-9 Zobrazit plný text záznamu